Tech Company Financing Transactions
Locanabio Funding Round
Locanabio secured a $100 million Series B funding round on 12/15/2020. Backers included Vida Ventures, Acuta Capital and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
12/15/2020
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
The financing will advance Locanabio's portfolio of RNA-targeted gene therapies and expand the technology platform to pursue a broad range of therapeutic indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3545 John Hopkins Ct. 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
We are creating a new class of precision medicines to treat a range of human genetic diseases. Locana's RNA-targeting technology platform allows us to precisely address these mutations on the level of RNA. By targeting RNA, our approach avoids the risk of off-target effects in DNA and is suited to address many diseases linked to dysfunctional processing of RNA.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Burns
Chief Scientific Officer
Kathie Bishop
Vice President
Adam Fowler
VP - Bus. Development
Micah Mackison
VP - Human Resources
Holly Winter
VP - Regulatory Affairs
Amy Jennings
Browse more venture capital transactions:
Prev: 12/15/2020: Homebuyer venture capital transaction
Next: 12/16/2020: Accelerist venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs